U.S. Markets closed
  • S&P 500

    4,471.37
    +33.11 (+0.75%)
     
  • Dow 30

    35,294.76
    +382.20 (+1.09%)
     
  • Nasdaq

    14,897.34
    +73.91 (+0.50%)
     
  • Russell 2000

    2,265.65
    -8.52 (-0.37%)
     
  • Gold

    1,768.10
    -29.80 (-1.66%)
     
  • EUR/USD

    1.1606
    +0.0005 (+0.0464%)
     
  • 10-Yr Bond

    1.5760
    +0.0570 (+3.75%)
     
  • Vix

    16.30
    -0.56 (-3.32%)
     
  • GBP/USD

    1.3751
    +0.0074 (+0.5418%)
     
  • USD/JPY

    114.2000
    +0.5230 (+0.4601%)
     
  • BTC-USD

    60,380.97
    -1,326.11 (-2.15%)
     
  • CMC Crypto 200

    1,464.06
    +57.32 (+4.07%)
     
  • FTSE 100

    7,234.03
    +26.32 (+0.37%)
     
  • Nikkei 225

    29,068.63
    +517.70 (+1.81%)
     

Earnings Preview for Recro Pharma

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Recro Pharma (NASDAQ:REPH) unveils its next round of earnings this Friday, February 26. Get prepared with Benzinga's ultimate preview for Recro Pharma's Q4 earnings.

Net Income, Earnings, And Earnings Per Share

Earnings and EPS are useful metrics of profitability. Total earnings also known as net income is equal to total revenue minus total expenses. Dividing net income by the total number of shares outstanding yields EPS.

Earnings And Revenue

Analysts are predicting Recro Pharma will report a loss of $0.25 per share on revenue of $15.00 million. Recro Pharma EPS in the same period a year ago totaled $0.38. Sales were $17.64 million.

Why Analyst Estimates And Earnings Surprises Are Important

Wall Street analysts who study this company will publish analyst estimates of revenue and EPS. The averages of all analyst EPS and revenue estimates are called the "consensus estimates"; these consensus estimates can have a significant effect on a company's performance during an earnings release. When a company posts earnings or revenue above or below a consensus estimate, it has posted an "earnings surprise", which can really move a stock depending on the difference between actual and estimated values.

View more earnings on REPH

If the company were to report earnings in line when it publishes results Friday, earnings would be up 34.21%. Sales would have fallen 14.98% from the same quarter last year. The company's reported EPS has stacked up against analyst estimates in the past like this:

EPS Estimate

-0.20

-0.16

-0.03

-0.25

EPS Actual

-0.09

-0.25

-0.33

-0.38

Revenue Estimate

16.33 M

18.88 M

19.45 M

19.55 M

Revenue Actual

19.29 M

15.52 M

21.78 M

17.64 M

Stock Performance

Shares of Recro Pharma were trading at $5.04 as of February 24. Over the last 52-week period, shares are down 65.34%. Given that these returns are generally negative, long-term shareholders are probably upset going into this earnings release.

Do not be surprised to see the stock move on comments made during its conference call. Recro Pharma is scheduled to hold the call at 16:30:00 ET and can be accessed here.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.